BeStock  
Stocks › Biotechnology › PTGX

Protagonist Therapeutics PTGX

US equityMarket cap rank #1605Biotechnology
$121.40 −$2.62 (-2.11%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $121.40 0.00%
Open$123.41
Prev close$124.02
Day range$120.15 – $125.91
Volume600.7K
Market cap$7.92B
P/E (TTM)25.7
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings27.7x
CheapRich

Above its usual level · 78th percentile, 5-year average 16.6x

#2056 of 2994 stocks by PE (1 = cheapest)

Price / book7.9x
CheapRich

Near the top of its 5-year range · 80th percentile, 5-year average 5.3x

#4797 of 5331 stocks by PB (1 = cheapest)

Price / sales15.5x
CheapRich

Below its usual level · 35th percentile, 5-year average 260.1x

#4656 of 5155 stocks by PS (1 = cheapest)

P/E over five years

-96x-9x78x164xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$120.20
Price vs. fair value+1.0%Close to the estimate
Star rating★★★☆☆
Economic moatNarrow
UncertaintyHigh
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 7.88 – 5.29 80% (pricier than usual) #4797 of 5331 (1 = cheapest)
PE 27.68 45.94 16.61 78% (pricier than usual) #2056 of 2994 (1 = cheapest)
PS 15.49 34.40 260.14 35% (cheaper than usual) #4656 of 5155 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on PTGX.

Sign in to join the discussion.

Scroll to Top